Submit Manuscript  

Article Details


New Benzimidazole-Derived Isothioureas as Potential Antileukemic Agents - Studies In Vitro

[ Vol. 11 , Issue. 4 ]

Author(s):

Miroslawa Koronkiewicz, Anna Romiszewska, Zdzislaw Chilmonczyk and Zygmunt Kazimierczuk   Pages 364 - 372 ( 9 )

Abstract:


Isothioureas are a class of amphiphilic compounds carrying a highly basic isothiourea group of pKa ranging between 10 and 11. Hence, they exist in protonated (cation) form at physiological pH, a characteristic is of key importance for their pharmacological activity. Recently, we have found that a number of S-pentabromobenzylisothiourea derivatives show substantial cytotoxicity toward a variety of human glioblastoma, leukemia, and adenocarcinoma cell lines. Whereas there is a growing body of data on aliphatic and alkylaromatic isothioureas, little attention was given to this day to heterocyclic isotiourea derivatives. Here we report on the synthesis and pharmacological in vitro properties of 10 novel S-(benzimidazol-2-ylmethyl)- and S-(5,6-dichlorobenzimidazol-2-ylmethyl)isothiourea derivatives. The compounds were obtained by the condensation of the respective 2-chloromethyl benzimidazoles with various substituted N(N’)-thioureas. Besides the essential physicochemical characteristics (H-NMR, UV, elemental analysis) of the new compounds, their log P values, which are of key importance for in vivo drug distribution and interactions, were determined. Pharmacological (anticancer) activity of the compounds was evaluated based on their ability to induce apoptosis in exponentially growing cultures of the human acute myelogenous leukemia cell line KG-1; the apoptosis was assessed with a variety of flow cytometric methods. Of the novel compounds tested, the most potent apoptosis inducer in KG-1 cells was N-methyl-S- (5,6-dichloro-1H-benzimidazol-2-ylmethyl)isothiouronium chloride (ClBMMe).

Keywords:

Antileukemic agents, apoptosis, benzimidazole isothioureas, flow cytometry, KG-1 cells.

Affiliation:

Department of Cell Biology, National Medicines Institute, Chelmska St. 30/34, 00-725 Warsaw, Poland.

Graphical Abstract:



Read Full-Text article